Key result
Individualized MHT and neurokinin antagonists emerge as key therapies for postmenopausal hypertension and vasomotor symptoms.
Why the study?
Postmenopausal hypertension has emerged as a major cardiovascular disorder contributing to morbidity and mortality in aging women, warranting examination of its pathophysiology, therapeutic strategies, and newer approaches.
Design
Review
Authors
Loading...
May warrant individualized MHT assessment; leaves open dedicated trials for neurokinin antagonists.
This review highlights the multifactorial pathophysiology of postmenopausal hypertension and supports individualized use of menopausal hormone therapy alongside emerging non-hormonal treatments.
Dr. Virendra Kushwaha* (2026) conducted a review in Postmenopausal hypertension. Menopausal hormone therapy and non-hormonal therapies was evaluated. Individualized menopausal hormone therapy and novel neurokinin receptor antagonists are emerging as key management strategies for postmenopausal hypertension and associated vasomotor symptoms.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: